Full text is available at the source.
Abstract
Clinical guidelines recommend the use of four specific drug classes to reduce cardiorenal risk.
- Renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists are suggested for combined use.
- Eligibility criteria for combination treatment among patients is not well defined.
- The potential impact of these combined treatments on mortality prevention is currently unclear.
Simplified